Search Results

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

Eli Lilly’s new research and development facility in Boston’s Seaport district will focus on DNA- and RNA-based therapies, as well as other priority areas such as diabetes and obesity.

Boston Pharmaceuticals today announced the appointment of Margaret Koziel, M.D., as Chief Medical Officer (CMO). Juan Carlos Lopez-Talavera, M.D., Ph.D., who has served as acting CMO since December 2023, will move to an advisory role to Dr. Koziel and the Boston Pharmaceuticals team as the company advances its promising late-stage candidate BOS-580.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

The closures follow Novartis’s acquisition of MorphyoSys earlier this year.

Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.